Fuzuloparib

A PARP inhibitor used in cancer treatment

Fuzuloparib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Fuzuloparib is a PARP inhibitor used in the treatment of certain types of cancer. It is particularly utilized in the management of ovarian cancer and other malignancies associated with BRCA mutations.

Mechanism of Action

Fuzuloparib functions by inhibiting the enzyme poly ADP ribose polymerase (PARP). PARP plays a critical role in the repair of single-strand DNA breaks through the base excision repair pathway. By inhibiting PARP, Fuzuloparib prevents the repair of these DNA breaks, leading to the accumulation of DNA damage in cancer cells. This accumulation ultimately results in cell death, particularly in cells deficient in homologous recombination repair, such as those with BRCA1 or BRCA2 mutations.

Clinical Use

Fuzuloparib is primarily indicated for the treatment of ovarian cancer in patients with deleterious or suspected deleterious BRCA mutations. It is also being investigated for use in other cancer types, including breast cancer and prostate cancer, where similar genetic vulnerabilities may be exploited.

Administration

Fuzuloparib is administered orally, allowing for convenient outpatient treatment. The dosing regimen typically involves daily administration, but specific dosing schedules may vary based on the clinical context and patient response.

Side Effects

Common side effects of Fuzuloparib include nausea, fatigue, anemia, and thrombocytopenia. Patients may also experience gastrointestinal disturbances such as vomiting and diarrhea. As with other PARP inhibitors, there is a risk of more serious adverse effects, including myelodysplastic syndrome and acute myeloid leukemia, although these are less common.

Research and Development

Fuzuloparib is the result of extensive research into targeted cancer therapies. It represents a significant advancement in the treatment of cancers with specific genetic profiles. Ongoing clinical trials are exploring its efficacy in combination with other anticancer agents and in a broader range of tumor types.

Related Pages

• Ovarian cancer
• BRCA mutation
• PARP inhibitor
• Breast cancer
• Prostate cancer